Can-Fite raises $4 million through warrant exercise agreement Mar 4, 2026 10:26AM
Can-Fite reports positive safety data for pancreatic cancer drug Mar 4, 2026 07:02AM
D. Boral Capital Downgrades Can-Fite BioPharma (CANF) to Hold Dec 24, 2025 10:42AM
Can-Fite announces 1-for-3,000 reverse stock split effective January 2026 Dec 23, 2025 04:47PM
Can-Fite advances Phase III trials, reports $6.45M cash position Dec 16, 2025 09:19AM


Nov 26, 2025 07:01AM Can-Fite CEO to present drug pipeline at Noble Capital conference
Nov 4, 2025 06:38AM H.C. Wainwright Assumes Can-Fite BioPharma (CANF) at Buy
Apr 14, 2025 02:29PM Can-Fite BioPharma (CANF) Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Apr 14, 2025 08:01AM Can-Fite BioPharma (CANF) Reports 2024 Financial Results and Clinical Update
Nov 12, 2024 07:51AM H.C. Wainwright Reiterates Buy Rating on Can-Fite BioPharma (CANF)
Nov 4, 2024 07:12AM Can-Fite BioPharma (CANF) anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Oct 18, 2024 09:11AM Can-Fite BioPharma (CANF): Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Aug 29, 2024 08:17AM Can-Fite BioPharma (CANF) Reports H1, Provides Updates on Two Pivotal Phase III Studies
Jul 17, 2024 07:01AM EF Hutton Starts Can-Fite BioPharma (CANF) at Buy
Jun 28, 2024 07:00AM Can-Fite BioPharma (CANF): Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
Jun 24, 2024 07:00AM Can-Fite BioPharma (CANF): Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver